imatinib mesylate has been researched along with Vomiting in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fujimaki, K; Ishigatsubo, Y; Miyashita, K | 1 |
| Agrawal, S; Baruchel, A; Beverloo, BB; den Boer, ML; Dworzak, M; Kearns, PR; Lancaster, DL; Lehrnbecher, T; Manos, G; Mechinaud, F; Pieters, R; Reinhardt, D; Rizzari, C; Rosenberg, J; Strauss, L; van der Velden, VH; Zwaan, CM | 1 |
| Brümmendorf, TH; Cortes, JE; Dmoszynska, A; Duvillié, L; Gambacorti-Passerini, C; Gogat Marchant, K; Kantarjian, HM; Khattry, N; Lipton, JH; Pavlov, D; Rossiev, V; Wong, RS | 1 |
| Li, QW; Lu, JY; Sun, JZ; Wang, RL; Xiao, WH; Zhu, JH | 1 |
| Deininger, MW; Druker, BJ; Ford, JM; O'Brien, SG | 1 |
| Alimena, G; Breccia, M; Carmosino, I; Latagliata, R; Morano, SG; Russo, E | 1 |
| Cortes, J; Daley, GQ; Ferrajoli, A; Jabbour, E; Kantarjian, H; Koller, C; O'Brien, S; Statkevich, P; Verstovsek, S; Zhu, Y | 1 |
| Benson, K; Chen, G; Cohen, MH; Duan, J; Gobburu, J; Johnson, JR; Kim, SK; Leighton, J; Pazdur, R; Rahman, A; Rothmann, M; Staten, AM; U, KM; Williams, G; Wood, R | 1 |
1 review(s) available for imatinib mesylate and Vomiting
| Article | Year |
|---|---|
Practical management of patients with chronic myeloid leukemia receiving imatinib.
Topics: Antineoplastic Agents; Arthralgia; Benzamides; Bone Marrow; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Eruptions; Drug Interactions; Edema; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Hematopoietic Cell Growth Factors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Liver; Muscle Cramp; Nausea; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Vomiting | 2003 |
3 trial(s) available for imatinib mesylate and Vomiting
| Article | Year |
|---|---|
Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium.
Topics: Adolescent; Antineoplastic Agents; Benzamides; Child; Child, Preschool; Dasatinib; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Headache; Humans; Imatinib Mesylate; Infant; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Nausea; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Sample Size; Therapies, Investigational; Thiazoles; Treatment Outcome; Vomiting; Young Adult | 2013 |
Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia.
Topics: Alanine Transaminase; Aniline Compounds; Antineoplastic Agents; Aspartate Aminotransferases; Benzamides; Diarrhea; Female; Fever; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Muscle Cramp; Myalgia; Nitriles; Pain; Piperazines; Pyrimidines; Quinolines; Vomiting | 2014 |
Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Piperidines; Pyridines; Pyrimidines; Treatment Failure; Treatment Outcome; Vomiting | 2007 |
4 other study(ies) available for imatinib mesylate and Vomiting
| Article | Year |
|---|---|
[Chronic myeloid leukemia maintained major molecular response with intermittent dosage of imatinib mesylate].
Topics: Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Pyrimidines; Vomiting | 2013 |
[Advanced dermatofibrosarcoma protuberans treated with imatinib mesylate].
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Dermatofibrosarcoma; Edema; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Male; Middle Aged; Nausea; Neoplasm Metastasis; Neoplasm Staging; Neutropenia; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Remission Induction; Skin Neoplasms; Survival Rate; Vomiting | 2011 |
Early and tardive skin adverse events in chronic myeloid leukaemia patients treated with imatinib.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Carcinoma; Drug Eruptions; Edema; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Nausea; Piperazines; Pyrimidines; Skin Neoplasms; Vomiting; Weight Gain | 2005 |
Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Benzamides; Capsules; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Diarrhea; Drug Approval; Exanthema; Headache; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nausea; Piperazines; Pyrimidines; Treatment Outcome; United States; United States Food and Drug Administration; Vomiting | 2002 |